Developing ‘Next-Gen’ Therapeutics: a First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC

Bispecific ADCs (bsADCs) are positioned as an emerging, next-generation, class of therapeutics, combining the dual-targeting capabilities of bispecific antibodies (bsAbs) with the potent cytotoxicity of antibody-drug conjugates (ADCs). The resulting bsADC offers improved efficacy and safety for the treatment of heterogeneous solid tumors.